130872Rapid low cost formulation screening for protein self-interaction based on High Performance Capillary ElectrophoresisClosedFeasibility StudiesInnovate UKThe advance in protein-based biopharmaceuticals represents the most innovative and lucrative development in the pharmaceutical industry. Treatment with mAbs has evolved from former high mortality diseases like cancer into modern day chronic illness, including Alzheimer’s disease, lupus, diabetes and chronic pain. With the increased need for biopharmaceutical products, protein aggregation (sticking together) due to protein self-interaction remains a enormous challenge in formulation. Our proposed feasibility study addresses the need for a cost-effective, user-friendly, automated platform technology that allows rapid screening for protein self-interactions. The successful development and commercialisation of our proposed platform technology will not only bring substantial cost savings to the pharmaceutical industry but also has the potential to free up hospital resource and improve patient experience by adopting innovative drug delivery systems.